Latest news and press releases about Bionano Genomics, Inc. (BNGO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles.
Price
| Price | $1.51 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.54 |
| EV / EBITDA | -0.75 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -78.78% |
| Return on Invested Capital | -83.76% |
| Return on Assets | -67.58% |
| Gross Margin | 47.50% |
| Operating Margin | -106.67% |
| Net Margin | -106.58% |
Related companies: AIM · BNBX · GBS · KTTA · MYNZ · NDRA · POAI
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BNGO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks